SEARCH

SEARCH BY CITATION

References

  • 1
    Dalgleish AG,Whelan MA. Cancer vaccines as a therapeutic modality: the long trek. Cancer Immunol Immunother 2006; 55: 102532.
  • 2
    Srivastava PK. Therapeutic cancer vaccines. Curr Opin Immunol 2006; 18: 2015.
  • 3
    Morisaki T,Matsumoto K,Onishi H,Kuroki H,Baba E,Tasaki A,Kubo M,Nakamura M,Inaba S,Yamaguchi K,Tanaka M,Katano M. Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives. Hum Cell 2003; 16: 17582.
  • 4
    Brossart P,Wirths S,Brugger W,Kanz L. Dendritic cells in cancer vaccines. Exp Hematol 2001; 29: 124755.
  • 5
    Xia D,Moyana T,Xiang J. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors. Cell Res 2006; 16: 24159.
  • 6
    Rosenberg SA,Zhai Y,Yang JC,Schwartzentruber DJ,Hwu P,Marincola FM,Topalian SL,Restifo NP,Seipp CA,Einhorn JH,Roberts B,White DE. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst 1998; 90: 1894900.
  • 7
    Brossart P,Goldrath AW,Butz EA,Martin S,Bevan MJ. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J Immunol 1997; 158: 32706.
  • 8
    Elzey BD,Siemens DR,Ratliff TL,Lubaroff DM. Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors. Int J Cancer 2001; 94: 8429.
  • 9
    Liu DW,Tsao YP,Hsieh CH,Hsieh JT,Kung JT,Chiang CL,Huang SJ,Chen SL. Induction of CD8 T cells by vaccination with recombinant adenovirus expressing human papillomavirus type 16 E5 gene reduces tumor growth. J Virol 2000; 74: 90839.
  • 10
    Miller G,Lahrs S,Pillarisetty VG,Shah AB,DeMatteo RP. Adenovirus infection enhances dendritic cell immunostimulatory properties and induces natural killer and T-cell-mediated tumor protection. Cancer Res 2002; 62: 52606.
  • 11
    McCluskie MJ,Weeratna RD. Novel adjuvant systems. Curr Drug Targets Infect Disord 2001; 1: 26371.
  • 12
    Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006; 5: 47184.
  • 13
    Baines J,Celis E. Immune-mediated tumor regression induced by CpG-containing oligodeoxynucleotides. Clin Cancer Res 2003; 9: 2693700.
  • 14
    Ballas ZK,Krieg AM,Warren T,Rasmussen W,Davis HL,Waldschmidt M,Weiner GJ. Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J Immunol 2001; 167: 487886.
  • 15
    Krieg AM. Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. Curr Oncol Rep 2004; 6: 8895.
  • 16
    Davila E,Celis E. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity. J Immunol 2000; 165: 53947.
  • 17
    Beloeil L,Tomkowiak M,Angelov G,Walzer T,Dubois P,Marvel J. In vivo impact of CpG1826 oligodeoxynucleotide on CD8 T cell primary responses and survival. J Immunol 2003; 171: 29953002.
  • 18
    Wingender G,Garbi N,Schumak B,Jungerkes F,Endl E,von Bubnoff D,Steitz J,Striegler J,Moldenhauer G,Tuting T,Heit A,Huster KM, et al. Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO. Eur J Immunol 2006; 36: 1220.
  • 19
    Salucci V,Mennuni C,Calvaruso F,Cerino R,Neuner P,Ciliberto G,La Monica N,Scarselli E. CD8+ T-cell tolerance can be broken by an adenoviral vaccine while CD4+ T-cell tolerance is broken by additional co-administration of a Toll-like receptor ligand. Scand J Immunol 2006; 63: 3541.
  • 20
    Lubaroff DM,Karan D,Andrews MP,Acosta A,Abouassaly C,Sharma M,Krieg AM. Decreased cytotoxic T cell activity generated by co-administration of PSA vaccine and CpG ODN is associated with increased tumor protection in a mouse model of prostate cancer. Vaccine 2006; 24: 615562.
  • 21
    Shariat SF,Desai S,Song W,Khan T,Zhao J,Nguyen C,Foster BA,Greenberg N,Spencer DM,Slawin KM. Adenovirus-mediated transfer of inducible caspases: a novel “death switch” gene therapeutic approach to prostate cancer. Cancer Res 2001; 61: 256271.
  • 22
    Carpentier A,Laigle-Donadey F,Zohar S,Capelle L,Behin A,Tibi A,Martin-Duverneuil N,Sanson M,Lacomblez L,Taillibert S,Puybasset L,Van Effenterre R, et al. Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neuro-oncol 2006; 8: 606.
  • 23
    Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 2004; 4: 24958.
  • 24
    Morris E,Hart D,Gao L,Tsallios A,Xue SA,Stauss H. Generation of tumor-specific T-cell therapies. Blood Rev 2006; 20: 619.
  • 25
    Ballas ZK,Rasmussen WL,Krieg AM. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol 1996; 157: 18405.
  • 26
    Hugues S,Fetler L,Bonifaz L,Helft J,Amblard F,Amigorena S. Distinct T cell dynamics in lymph nodes during the induction of tolerance and immunity. Nat Immunol 2004; 5: 123542.
  • 27
    Meyer-Olson D,Brady KW,Bartman MT,O'Sullivan KM,Simons BC,Conrad JA,Duncan CB,Lorey S,Siddique A,Draenert R,Addo M,Altfeld M, et al. Fluctuations of functionally distinct CD8+ T-cell clonotypes demonstrate flexibility of the HIV-specific TCR repertoire. Blood 2006; 107: 237383.
  • 28
    Murali-Krishna K,Altman JD,Suresh M,Sourdive D,Zajac A,Ahmed R. In vivo dynamics of anti-viral CD8 T cell responses to different epitopes. An evaluation of bystander activation in primary and secondary responses to viral infection. Adv Exp Med Biol 1998; 452: 12342.
  • 29
    Marzo AL,Klonowski KD,Le Bon A,Borrow P,Tough DF,Lefrancois L. Initial T cell frequency dictates memory CD8+ T cell lineage commitment. Nat Immunol 2005; 6: 7939.
  • 30
    Rosenberg SA,Yang JC,Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10: 90915.
  • 31
    Bronte V,Kasic T,Gri G,Gallana K,Borsellino G,Marigo I,Battistini L,Iafrate M,Prayer-Galetti T,Pagano F,Viola A. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med 2005; 201: 125768.
  • 32
    Coulie PG,van der Bruggen P. T-cell responses of vaccinated cancer patients. Curr Opin Immunol 2003; 15: 1317.
  • 33
    Gattinoni L,Klebanoff CA,Palmer DC,Wrzesinski C,Kerstann K,Yu Z,Finkelstein SE,Theoret MR,Rosenberg SA,Restifo NP. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 2005; 115: 161626.
  • 34
    Makki A,Weidt G,Blachere NE,Lefrancois L,Srivastava PK. Immunization against a dominant tumor antigen abrogates immunogenicity of the tumor. Cancer Immun 2002; 2: 4.
  • 35
    Rosenberg SA,Sherry RM,Morton KE,Scharfman WJ,Yang JC,Topalian SL,Royal RE,Kammula U,Restifo NP,Hughes MS,Schwartzentruber D,Berman DM, et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol 2005; 175: 616976.
  • 36
    Boon T,Coulie PG,Eynde BJ,Bruggen PV. Human T Cell Responses against Melanoma. Annu Rev Immunol 2006; 24: 175208.
  • 37
    Porgador A,Snyder D,Gilboa E. Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol 1996; 156: 291826.
  • 38
    Rosenblatt J,Kufe D,Avigan D. Dendritic cell fusion vaccines for cancer immunotherapy. Expert Opin Biol Ther 2005; 5: 70315.
  • 39
    Krieg AM,Yi AK,Matson S,Waldschmidt TJ,Bishop GA,Teasdale R,Koretzky GA,Klinman DM. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374: 5469.
  • 40
    Gendron KB,Rodriguez A,Sewell DA. Vaccination with human papillomavirus type 16 E7 peptide with CpG oligonucleotides for prevention of tumor growth in mice. Arch Otolaryngol Head Neck Surg 2006; 132: 32732.
  • 41
    Wille-Reece U,Flynn BJ,Lore K,Koup RA,Miles AP,Saul A,Kedl RM,Mattapallil JJ,Weiss WR,Roederer M,Seder RA. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J Exp Med 2006; 203: 124958.
  • 42
    Li WM,Dragowska WH,Bally MB,Schutze-Redelmeier MP. Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes. Vaccine 2003; 21: 331929.
  • 43
    Speiser DE,Lienard D,Rufer N,Rubio-Godoy V,Rimoldi D,Lejeune F,Krieg AM,Cerottini JC,Romero P. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 2005; 115: 73946.
  • 44
    Estcourt MJ,Letourneau S,McMichael AJ,Hanke T. Vaccine route, dose and type of delivery vector determine patterns of primary CD8+ T cell responses. Eur J Immunol 2005; 35: 253240.
  • 45
    Mellor AL,Baban B,Chandler PR,Manlapat A,Kahler DJ,Munn DH. Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling. J Immunol 2005; 175: 56015.
  • 46
    Kumar S,Jones TR,Oakley MS,Zheng H,Kuppusamy SP,Taye A,Krieg AM,Stowers AW,Kaslow DC,Hoffman SL. CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine. Infect Immun 2004; 72: 94957.
  • 47
    Schneeberger A,Wagner C,Zemann A,Luhrs P,Kutil R,Goos M,Stingl G,Wagner SN. CpG motifs are efficient adjuvants for DNA cancer vaccines. J Invest Dermatol 2004; 123: 3719.
  • 48
    Sugauchi F,Wang RY,Qiu Q,Jin B,Alter HJ,Shih JW. Vigorous hepatitis C virus-specific CD4+ and CD8+ T cell responses induced by protein immunization in the presence of Montanide ISA720 plus synthetic oligodeoxynucleotides containing immunostimulatory cytosine-guanine dinucleotide motifs. J Infect Dis 2006; 193: 56372.
  • 49
    Jiang JQ,Patrick A,Moss RB,Rosenthal KL. CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides. J Virol 2005; 79: 393400.
  • 50
    La Rosa C,Wang Z,Lacey SF,Lalimarmo MM,Krishnan A,Longmate J,Diamond DJ. In vitro expansion of polyclonal T-cell subsets for adoptive immunotherapy by recombinant modified vaccinia Ankara. Exp Hematol 2006; 34: 497507.
  • 51
    Storni T,Bachmann MF. On the role of APC-activation for in vitro versus in vivo T cell priming. Cell Immunol 2003; 225: 111.
  • 52
    Storni T,Lechner F,Erdmann I,Bachi T,Jegerlehner A,Dumrese T,Kundig TM,Ruedl C,Bachmann MF. Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles. J Immunol 2002; 168: 28806.
  • 53
    Storni T,Ruedl C,Schwarz K,Schwendener RA,Renner WA,Bachmann MF. Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J Immunol 2004; 172: 177785.
  • 54
    Walter U,Santamaria P. CD8+ T cells in autoimmunity. Curr Opin Immunol 2005; 17: 62431.
  • 55
    Refaeli Y,Van Parijs L,Alexander SI,Abbas AK. Interferon gamma is required for activation-induced death of T lymphocytes. J Exp Med 2002; 196: 9991005.